Study of COVID antibody levels in healthcare workers
Part of Infections, Lungs & breathing clinical trials.
This study measures how many healthcare workers have COVID antibodies (proof of past infection or immune response). Results may help estimate how widespread COVID exposure has been among hospital staff.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You must work for or be affiliated with NewYork-Presbyterian (NYP) as healthcare staff
- You must be able to read and understand English
- You must be able to complete study tasks (mentally and physically)
- If you cannot do the study tasks, you cannot join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gathers information about healthcare workers (adults) and tracks your past COVID-19 infection and vaccination history. It may help researchers understand how COVID affects healthcare workers and how vaccines relate to infection outcomes.
This study looks at how the immune system responds to COVID-19 in healthcare workers and infected patients at Danderyd Hospital. It aims to understand immunity and help guide future care.
This research study examines a specific type of antibody (anti-annexin A2) that may develop during COVID-19 infection. By studying hospitalized COVID-19 patients, researchers hope to understand whether these antibodies are common and what role they might play in COVID-19 illness.
This study looks at how people’s immune protection after COVID-19 may change over time. It aims to better understand immunity, which could help doctors plan future care and prevention.
This study looks at how obesity affects the body's response to severe COVID-19. It compares people with obesity to healthy-weight healthcare workers to understand differences in the immune system.
This study looks at how the body's immune system reacted to COVID-19 in people who had either severe or mild cases. The goal is to learn more about a specific part of the immune response (called IFN-I) to better understand the disease.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.